Imunon’s stock rockets after ovarian cancer treatment’s positive trial results

Imunon’s stock skyrocketed on massive volume Tuesday, after the biotechnology company announced positive survival data from a trial of its ovarian cancer treatment, IMNN-001.

Previous post Pershing Square USA officially scales back IPO for debut in coming weeks
Next post Standard Chartered lifts guidance and launches record $1.5 billion share buyback